Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Portable airway inflammation measurement device

Aerocrine : 13 September, 2013  (New Product)
Designed for diagnosing airway inflammation in sufferers of Asthma, the hand-held Niox Vero measurement device improves asthma patient care
Portable airway inflammation measurement device


Aerocrine announces the launch of Niox Vero, a new, fully portable hand-held point-of-care device for the measurement of airway inflammation, such as asthma. Aerocrine introduces the new device in conjunction with the European Respiratory Society (ERS) annual meeting in Barcelona takeing place on September 7-11, 2013. Niox Vero was developed in collaboration between Aerocrine and Panasonic Healthcare.



Niox Vero is a new and upgraded version of the gold standard for measurement of Fractional exhaled Nitric Oxide (FeNO), a validated and clinically proven method for assessing allergic airway inflammation such as asthma. Niox Vero provides accurate, reproducible and rapid measurement results. The Niox Vero has an onboard, rechargeable battery, upgraded software, wireless technology, patient journalling and has a useful life of 15,000 tests or 5 years compared to its predecessor's (Niox Mino) 3,000 tests or 3 years.



The CE-marked device used to measure airway inflammation - an underlying cause of inflammatory airway diseases – helps physicians to improve patient outcomes and reduce healthcare expenditures. The product is a complement to the Aerocrine product portfolio and will be initially introduced in selected market segments in Q4 2013 (Sweden, United Kingdom and Germany). The objective of this initial introduction is to conduct a real-life handling test of this highly innovative device in the daily practice of a limited number of demonstration sites. Further introduction in the remaining European countries is expected during spring 2014. Among the benefits of Niox Vero, physicians will have more objective insights into treatment effectiveness and can better predict a patients’ response to therapy and the risk of an asthma relapse. Moreover, physicians will be able to identify patient non-compliance with medications, and can adjust the dose of medication based on individual patients’ needs. By using Niox Vero doctors can measure the underlying inflammation that causes asthma within a few minutes directly in their offices.



Asthma is a chronic disease affecting millions including many children. Aerocrine’s Niox products are created to help physicians identify patients that will respond to the optimal therapy. Patients are different, requiring different treatments and dosages. Therefore, airway inflammatory disease management and control can be significantly improved through ‘personalized’ monitoring of the airway inflammation rather than just following symptoms and assessing lung function.


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo